Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 26, 2006

Cerus Receives $5M Milestone Payment

  • Cerus received a $5-million cash milestone payment from BioOne triggered by the CE mark regulatory approval for its INTERCEPT Blood System for plasma in Europe. The agreements between Cerus and BioOne provide for milestone payments to Cerus as well as royalties based on sales of the INTERCEPT Blood System for platelets and plasma.

    Cerus also expects an addition payment of BioOne preferred stock worth $5 million in early 2007. Upon receipt of the cash milestone payment, Cerus forwarded $0.5 million to Baxter Healthcare according to an agreement relating to the BioOne commercialization rights.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »